

Product Information

Product ID V1600
CAS No. 1232410-49-9
Chemical Name

Synonym VE821

Formula $C_{18}H_{16}N_4O_3S$
Formula Wt. 368.41

Melting Point


Purity $\geq 98\%$

Solubility DMSO 74 mg/mL (200.86
mM)
Water Insoluble
Ethanol Insoluble

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description VE-821 is an inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase, a chromatin-remodeling protein that senses DNA damage and activates the DNA damage checkpoint to induce cell cycle arrest. VE-821 exhibits anticancer activity, inducing chromosome fragmentation, apoptosis, and cell death in vitro. VE-821 decreases phosphorylation of checkpoint kinase (CHK) 1 and induces G2 phase cell cycle arrest in pancreatic cancer cells and leukemia cells, sensitizing them to the effects of radiation.



Pricing and Availability

Bulk quantities available upon request

| Product ID | Size | List Price |
|------------|-------|------------|
| V1600 | 1 mg | \$82.70 |
| V1600 | 5 mg | \$161.10 |
| V1600 | 10 mg | \$247.70 |

References Flynn RL, Cox KE, Jeitany M, et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. *Science*. 2015 Jan 16;347(6219):273-7. PMID: 25593184.

Vávrová J, Zárybnická L, Lukášová E, et al. Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60). *Radiat Environ Biophys*. 2013 Nov;52(4):471-9. PMID: 23934411.

Prevo R, Fokas E, Reaper PM, et al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. *Cancer Biol Ther*. 2012 Sep;13(11):1072-81. PMID: 22825331.

Reaper PM, Griffiths MR, Long JM, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. *Nat Chem Biol*. 2011 Apr 13;7(7):428-30. PMID: 21490603.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.